Oncology The impact of cancer on male sexual function For many men, sex remains important throughout life – and that includes after a cancer diagnosis.
R&D Trajectory-based diagnostics enable early intervention in pr... Diagnostic testing in modern medicine remains largely episodic and threshold-based.
News J&J bids to extend prostate cancer uses for Akeega J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
News BMS' radiopharma unit builds with $1.35bn Philochem deal Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.
News ASCO 25: J&J combo pill may see wider use in prostate cancer AMPLITUDE study of J&J's Akeega could extend the use of PARP inhibitors to hormone-responsive prostate cancer.
Oncology Prostate cancer: HCPs discuss emerging treatments, artificia... In March, the UK marked Prostate Cancer Awareness Month - a period dedicated to boosting recognition and tackling stigma of a cancer that affects approximately one in eight men nationwide.<
News Novavax critic Shah Capital ends its activism campaign Shah Capital has ended attempts to exert influence over vaccine firm Novavax, bringing more than years of pressure on management to an end.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
